Novocure's Optune Pax Approved in Japan for Pancreatic Cancer
Novocure announced that Japan's Ministry of Health, Labour and Welfare approved Optune Pax for adult patients with unresectable locally advanced pancreatic cancer, when used concomitantly with gemcitabine and nab-paclitaxel.
Novocure (NASDAQ:NVCR) said today Japan’s Ministry of Health, Labour and Welfare (MHLW) approved Optune Pax® for use in adult patients diagnosed with unresectable locally advanced pancreatic cancer, to be used with gemcitabine and nab-paclitaxel. “The approval of Optune Pax prov…